FFM
THRX

Fairmount Funds Management’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Fairmount Funds Management’s Portfolio THRX Stock Details THRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,865,671
Closed -$16.6M – 20
2023
Q1 		$16.6M Buy
+1,865,671
New +$18.3M 2.85% 12

Other funds holding THRX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Fairmount Funds Management's THRX Position: Q2 2023 in Review

Fairmount Funds Management sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q2 2023, closing a stake of 1,865,671 shares — an estimated $16.6M sold.

Fairmount Funds Management first reported a position in THRX in Q1 2023 and held it in 1 quarter. The position peaked at $16.6M in Q1 2023. 69 funds tracked by Wall St. Rank hold THRX as of Q2 2023.

  • Fairmount Funds Management reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Fairmount Funds Management sold 1,865,671 Theseus Pharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $16.6M.
  • Fairmount Funds Management first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Fairmount Funds Management's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $16.6M in Q1 2023.
  • 69 funds tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Fairmount Funds Management's 13F filing for Q2 2023, filed 14 Aug 2023.